MedTrace Logo

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

NCT05985161 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.

Conditions

  • Wilms Tumor
  • Rhabdoid Tumor
  • Malignant Peripheral Nerve Sheath Tumors
  • MPNST
  • Nephroblastoma
  • XPO1 Gene Mutation
  • Solid Tumor

Interventions

DRUG

Selinexor

This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (maximum dose 100mg/dose) once weekly using a liquid suspension .

Sponsors & Collaborators

Principal Investigators

  • Michael Ortiz, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2029-08-01
Completion
2029-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05985161 on ClinicalTrials.gov